<a href="https://www.fiercebiotech.com/biotech/compass-usona-score-fda-national-priority-vouchers-amid-trump-administrations-psychedelic" hreflang="en">Compass, Usona and Transcend score FDA national priority vouchers amid Trump administration’s psychedelic push</a>
The FDA has awarded national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics to expedite the development of psychedelic treatments for mental health disorders, in line with the Trump administration's push to enhance access to such therapies. These vouchers will facilitate improved communication with the FDA and accelerate the review process for their respective psilocybin and methylone treatments.
The FDA's issuance of national priority vouchers to companies like Compass Pathways and Transcend Therapeutics underscores a significant regulatory shift towards accelerating the development and approval of psychedelic medicines for mental health disorders such as treatment-resistant depression and PTSD. For professionals in healthtech and biotech, this signals a potential surge in investment and collaboration opportunities in the burgeoning field of psychedelic therapies, particularly as these treatments gain regulatory support and demonstrate promising clinical outcomes.